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Introduction. Acute Kidney Injury (AKI) is common and associated with signiﬁcant mortality and complications. Exact data
on the epidemiology of AKI in the Emergency Department (ED) are sparse. This review aims to summarise the key principles
for managing AKI patients in the ED. Principal Findings. Timely resuscitation, goal-directed correction of ﬂuid depletion and
hypotension,andappropriatemanagementoftheunderlyingillnessareessentialinpreventingorlimitingAKI.Thereisnospeciﬁc
curative therapy for AKI. Key principles of secondary prevention are identiﬁcation of patients with early AKI, discontinuation
of nephrotoxic medication where possible, attention to ﬂuid resuscitation, and awareness of the risks of contrast-induced
nephropathy. In patients with advanced AKI, arrangements for renal replacement therapy need to be made before the onset of
life-threateninguraemiccomplications.Conclusions.ResearchandguidelinesregardingAKIintheEDarelackingandAKIpractice
from critical care departments should be adopted.
1.Introduction
Acute kidney injury (AKI) is common in hospitalised pa-
tients, especiallyin those who are critically ill [1, 2].The Kid-
ney Disease Improving Global Outcomes (KDIGO) work-
ing group estimates a worldwide AKI prevalence of ∼2100
people per million population [3].
There is increasing recognition that even a minor acute
reduction in renal function is independently associated with
a poor outcome, including higher risk of complications,
longer stay in hospital, high mortality, and increased risk
of needing long-term dialysis [4–9]. Although there is no
curative therapy for AKI, research over the past decade has
identiﬁed various means to prevent or limit AKI. Unfortu-
nately, these are not widely known and are variably practised
worldwide resulting in lost opportunities to improve the care
and outcomes of patients with AKI. Importantly, there is
no unifying approach to the care of these patients. There
is a worldwide need to recognise patients at risk of AKI,
to intervene early, and to circumvent the need for renal
replacement therapy (RRT).
Although a large proportion of patients presenting to the
Emergency Department (ED) either have AKI or develop
AKI later in hospital, the literature regarding epidemiology
and management of such patients in the ED setting is
lacking. In the UK, the recent National Conﬁdential Enquiry
into Patient Outcomes and Death (NCEPOD) report found
that AKI is often underrecognised and poorly managed.
T h er e p o r tm a d eas t r o n gc a l lf o rb e t t e re d u c a t i o na n d
training [10]. To our best knowledge, neither the College of
Emergency Medicine (UK), American College of Emergency
Physicians, Australasian College for Emergency Medicine,
nor Canadian Association of Emergency Physicians have
published guidelines on management of AKI in the ED.
This review aims to summarise existing knowledge about
the management of AKI with particular emphasis on speciﬁc
patient groups in the ED setting.
2. Deﬁnition of AKI
The literature contains >50 deﬁnitions for AKI which has
posed signiﬁcant problems for comparative epidemiology2 Emergency Medicine International
Table 1: Classiﬁcations to deﬁne AKI.
(a) RIFLE classiﬁcation [11]
RIFLE category SCr/GFR criteria Urine output criteria
Risk ↑ SCr ≥150–200% (1.5–2 fold) OR decrease of GFR >25% Urine output <0.5mL/kg/hour for 6 hours
Injury ↑ SCr >200–300% (>2-3 fold) OR decrease of GFR >50% Urine output <0.5mL/kg/hour for 12 hours
Failure
↑ SCr >300% (>3 fold) from baseline OR decrease of GFR
>75% OR serum creatinine ≥4mg/dL with an acute rise
of ≥44µmol/L
Urine output <0.3mL/kg/hour for 24 hours OR anuria
for 12 hours
Loss Complete loss of renal function for >4w e e k s
End stage kidney
disease
Need for RRT for >3m o n t h s
(b) AKI Network classiﬁcation [12]
AKIN stage Serum creatinine criteria Urine output criteria
1
↑ SCr ≥26.4µmol/L in ≤48 hours OR ↑ SCr
≥150–200% (1.5–2 fold) from baseline <0.5mL/kg/h for >6h
2 ↑ SCr >200–300% (>2–3 fold) from baseline <0.5mL/kg/h for >12 h
3
↑ SCr >300% (>3 fold) from baseline OR SCr
≥354µmol/L with an acute rise of ≥44µmol/L OR
treatment with RRT
<0.3mL/kg/h for 24 h OR
anuria for 12 h
(c) KDIGO classiﬁcation [3]
Stage Serum creatinine criteria Urine output criteria
1 1.5–1.9 times baseline OR ≥0.3mg/dL (>26.5µmol/L)
in ≤48 hours <0.5mL/kg/h for 6–12 hours
2 2–2.9 times baseline <0.5mL/kg/h for ≥12 hours
3
≥3 times baseline OR increase in SCr to ≥4.0mg/dL
(353.6µmol/L) OR initiation of RRT <0.3mL/kg/h for ≥24 hours OR anuria for ≥12 hours
Abbreviations: GFR: glomerular ﬁltration rate; RRT: renal replacement therapy; SCr: serum creatinine.
Only one criterion needs to be met to be classiﬁed as AKI; if both are present, the criterion which places the patient in the higher stage of AKI is selected.
and clinical research. In the last 10 years, eﬀorts have
been made to standardise the deﬁnition of AKI. In 2004,
the Risk-Injury-Failure-Loss-Endstage (RIFLE) criteria were
published, followed by the revised AKI Network (AKIN)
classiﬁcation in 2007 [11, 12]( Table 1). Both deﬁnitions will
soon be superceded by the KDIGO criteria which deﬁne AKI
by any of the following:
(i) increase in serum creatinine by ≥0.3mg/dL (>26.5
µmol/L) within 48 hours;
(ii) increase in serum creatinine to ≥1.5 times baseline,
which is known or presumed to have occurred within
p r i o r7d a y s ;o r
(iii) urine volume <0.5mL/kg/h for 6 hours.
The scale of the AKI burden in ED is not known. How-
ever, the key issue is that even relatively minor acute changes
in serum creatinine independent of underlying aetiology
represent signiﬁcant deterioration of renal function and are
associated with poor outcome [4].
3.Pathophysiology ofAKI
There is increasing evidence that AKI is an inﬂammatory
process involving complex interactions between vascular,
tubular, and inﬂammatory factors. It is often precipitated
by sepsis/systemic inﬂammatory response syndrome, renal
hypoperfusion, volume depletion, and nephrotoxicity. In
most cases, the aetiology is multifactorial. Patients with pre-
existing comorbidities including diabetes, cirrhosis/hepatic
failure, congestive heart failure, pre-existing chronic kidney
disease (CKD), peripheral vascular disease and advanced age
are at particular risk of AKI during an acute illness.
4.Diagnosisof AKI
The symptoms of AKI may be vague, nonspeciﬁc, or even
absent. The diagnosis of AKI currently depends on detection
of reductions in kidney function by conventional surro-
gate markers, such as serum creatinine and urine output.
However, both are known to have signiﬁcant limitations.
Furthermore, the RIFLE, AKIN, and KDIGO criteria for
AKI are based on relative changes in serum creatinine from
baseline. If a baseline creatinine is not known it would seem
prudent to assume that any elevated laboratory creatinine
is AKI until proven otherwise. Furthermore, creatinine rises
are typically seen 24–36 hours after the initial insult which
means that critically ill patients may already have signiﬁcant
AKI even if their serum creatinine has not changed yet.Emergency Medicine International 3
Table 2: Diagnostic work-up of patients with AKI.
Investigations Comments
Essential tests
Urinalysis Proteinuria and/or haematuria represent an active urinary sediment
suggestive of glomerular disease
Serum creatinine, urea and electrolytes
Full blood count and blood ﬁlm To rule out thrombotic mircoangiopathy and haemolysis;
eosinophilia may be present with interstitial nephritis
C-reactive protein elevated in inﬂammatory diseases and/or infections
Arterial or venous bicarbonate
Investigations to be considered depending on history and/or
clinical signs
Creatine kinase To rule out rhabdomyolysis
Serum and urine protein electrophoresis To rule out myeloma
Antinuclear antibody (ANA) In case of possible diagnosis of SLE or connective tissue disease
Antineutrophil antibody (ANCA) In case of possible systemic vasculitis
Anti-streptolysin O titres To rule out post streptococcal glomerulonephritis
Anti-glomerular basement membrane antibody To rule out Goodpasture’s disease
Complement levels Reduced in SLE, infectious endocarditis and cryoglobulinaemia
Hep B, Hep C and HIV serology To rule out renal disease caused by viral infections
Renal ultrasound To assess renal size; to rule out obstruction and chronic kidney
damage
The diagnostic workup of patients with AKI depends on the
history, clinical signs, and patient characteristics (Table 2).
5. Management of AKI
Early recognition of at-risk patients is paramount followed
by timely resuscitation with ﬂuids and/or vasoactive drugs
and prevention of further renal insults.
5.1. Fluid Therapy. The most commonly used ﬂuids are
crystalloidsandcolloids,includinggelatins,humanalbumin,
and hydroxyethyl starches (HES) with varying eﬀects on vol-
umeexpansion.Ideally,balancedcrystalloidsolutionsshould
be used, as 0.9% saline is associated with hyperchloremic
metabolic acidosis and worsening acid-base balance. Data
on the safety of diﬀerent colloids are conﬂicting [13].
High molecular weight HESs have been associated with an
increased risk of AKI, greater need for RRT, and higher
mortality and should therefore be avoided [14–16]. Human
albumin has been judged to be safe [14].
Although timely ﬂuid resuscitation is important to
prevent AKI in conditions associated with volume depletion,
there is increasing evidence that excessive ﬂuid adminis-
tration can be harmful and lead to dysfunction of other
organs and adverse outcomes [17, 18]. To avoid both hypo-
and hypervolaemia, patients need to be assessed regularly,
and ﬂuid prescriptions should be individualised and tailored
to the cardiovascular status of the patient. Ultrasound
sonography has emerged as a tool to aid the evaluation
of ﬂuid status and response to ﬂuid challenges [19, 20].
However, if in doubt, invasive haemodynamic monitoring
may be necessary to distinguish ﬂuid responsive patients
from those who are hypotensive due to vasodilation.
5.2. Vasoactive Drugs. In healthy conditions, renal blood
ﬂow is stable within a wide range of mean arterial pressure
(MAP) due to renal autoregulation. However, in critically
ill patients, in particular in septic shock, derangements in
microcirculationandvasoreactivitytendtoincreasetheMAP
threshold that guarantees autoregulation. Data on the opti-
mal MAP to prevent the development and/or progression
of AKI are conﬂicting. Current recommendations for the
prevention of AKI in the ICU propose to achieve a MAP
≥65mmHg but indicate that this target pressure should be
individualised when possible, especially in patients with pre-
existing chronic hypertension [15]. There is good evidence
that Noradrenaline in vasodilatory shock can increase renal
blood ﬂow, restore urine output, and improve creatinine
clearance [21, 22]. In contrast, there is no role for “renal-
dose” dopamine in either preventing or ameliorating AKI in
critically ill patients [23, 24].
5.3. Diuretics. There is no role for diuretics in preventing or
treatingestablishedAKI.Threemeta-analysesconﬁrmedthat
the use of diuretics in established AKI did not improve renal
function or change mortality but carried a signiﬁcant risk of
side eﬀects, including electrolyte derangement, ototoxicity,
and vestibular dysfunction [25–27]. There is also no role
for diuretics in speeding up recovery of renal function [28].
However, in patients with progressive ﬂuid accumulation,
diuretics can minimize ﬂuid overload and may make patient
management easier, especially if RRT is not immediately
available.4 Emergency Medicine International
5.4. Other Pharmacological Therapies. There is no evidence
for routine use of natriuretic peptide, aprotinin, thyroxine,
statins, activated protein C, steroids, or calcium channel
blockers to prevent AKI in patients who are critically ill
[15, 29, 30].
5.5. Discontinuation of Potentially Nephrotoxic Drugs. To-
gether with targeted ﬂuid and haemodynamic resuscitative
procedures, it is essential to stop/limit all nephrotoxic drugs.
When selected medications are considered vital, doses need
tobeadjustedregularlybasedonchangestokidney function.
6. Prevention of AKI in Speciﬁc
Patient Groups
6.1. Cardiac Disease. The incidence of AKI in acute decom-
pensated heart failure and acute coronary syndrome is esti-
matedtobe24–45%and9–19%,respectively[31].Anytreat-
ment for acute heart failure aimed at increasing cardiac
output and renal blood ﬂow should also lead to improved
renal function. Therapeutic options include ﬂuid therapy,
inotropic support and if necessary, cautious introduction of
noradrenaline but occasionally more invasive treatments like
an intra-aortic balloon pump or left ventricular assist device
may be required.
6.2. Rhabdomyolysis. Estimates from small studies suggest
that 20–50% of patients with rhabdomyolysis develop AKI as
a result of intravascular ﬂuid depletion, ﬂuid sequestration
in injured muscle, renal hypoperfusion, intratubular heme
pigment cast formation, and tubular obstruction. There may
be additional secondary renal injury due to free radical pro-
ductionandmyoglobin-inducednitricoxidescavenging.The
cornerstone for prevention of myoglobinuric AKI consists
of aggressive volume resuscitation with isotonic crystalloid
solutions at 10–15mL/kg/hr aiming for a target urine output
of >200mL/hr [32]. Isotonic bicarbonate (NaHCO3) at 50–
100mmol/L can be added aiming for a urine pH > 6.5
to increase the solubility and renal excretion of tubular
myoglobin.Althoughtherearetheoreticalbeneﬁtsforadding
mannitol (inhibition of intratubular myoglobin deposition
and cast formation, and osmotic diuresis), these beneﬁts are
not supported by randomised controlled trials [33].
6.3. Contrast Exposure. The risk of developing contrast-
induced nephropathy (CIN) is determined by pre-existing
renal function, presence of risk factors, and the volume
of radiocontrast agent. Patients with advanced age, dia-
betes, pre-existing CKD, haemodynamic instability, and my-
eloma are at particular risk. Crystalloid ﬂuids are usually
recommended for prevention [15, 34]. Both protocolised
administration of 0.9% saline or isotonic NaHCO3 have
the potential to reduce the incidence of CIN with some
evidence that sodium bicarbonate may be superior to saline.
The role of N-Acetylcysteine (NAC) is controversial due to
inconsistent results observed across multiple studies. Several
meta-analyses have reported a risk reduction with NAC but
also highlighted signiﬁcant study heterogeneity and positive
reporting bias [35–38]. In addition, concern has been raised
that the variable eﬃcacy of intravenous NAC against CIN
could be explained by diﬀerences in study populations and
direct eﬀects of NAC on measured serum creatinine levels.
As a result, the working party of the European Society
of Intensive Care suggests not to use NAC as prophylaxis
against CIN [15]. In contrast, the American Thoracic Society
Ad Hoc Committee on Acute Renal Failure recommended
that in patients at high risk of CIN, intravenous NAC in
combination with ﬂuids may be considered but pointed out
that the evidence was not suﬃcient [34]. Diabetic patients
who are taking metformin are at risk of developing lactic
acidosis following contrast exposure, especially in case of
pre-existing CDK [39]. It seems prudent to discontinue
metformin for at least 48 hours after contrast exposure and
to restart it only if there are no signs of nephrotoxicity.
7. Management of Uraemic Complications
In patients with advanced AKI, renal support should be
started before the onset of life-threatening uraemic com-
plications. In fact, many patients develop AKI in the com-
munity but may not present to the Emergency Department
untiltheydevelopuraemicsymptoms.PatientswithAKIand
progressive hyperkalaemia (K+ > 6.5mmol/L), refractory
metabolic acidosis, progressive pulmonary oedema, and/or
uraemic pericarditis need to be referred to the renal or
critical care team urgently. Whilst waiting for RRT, medical
treatment may be considered.
7.1. Medical Treatment of Hyperkalaemia. Severe hyper-
kalaemia (serum potassium >6.5mmol/litre) can cause car-
diac arrhythmias and should be treated immediately. Initial
management consists of stabilization of the myocardium
with calcium gluconate or calcium chloride [40]. Although
this is a short-term measure only and will not reduce
serum potassium, it reduces the arrhythmic threshold. A
recent review by the Cochrane Collaboration conﬁrmed
that inhaled beta-agonists, nebulised beta-agonists, and
intravenous insulin and glucose were all eﬀective at reduc-
ing potassium levels, in particular when administered in
combination [40]. The evidence for the use of intravenous
NaHCO3 to treat hyperkalaemia was considered to be
equivocal. Potassium-absorbing resins have no role in the
emergency management of hyperkalaemia mainly due to the
delay in eﬀect. There is also no clear evidence that means
to increase urine output and potassium excretion (e.g., by
ﬂuid resuscitation or by loop diuretics) are suﬃcient to
correct hyperkalaemia. If medical therapy fails to correct
hyperkalaemia, RRT needs to be considered.
7.2. Medical Management of Fluid Overload/Pulmonary
Oedema. If signiﬁcant respiratory failure is present, this
must be dealt with urgently, through supplementary oxy-
gen, noninvasive ventilation, or intubation and ventilation,
depending on the state of the patient [41]. While these
measures are being undertaken, pharmacological treatment
to induce diuresis and oﬄoad the decompensated heart can
be started, including intravenous opioids, an intravenousEmergency Medicine International 5
infusion of nitrate and diuretics to provoke a diuresis.
Converting oliguric to nonoliguric renal failure may help
with ﬂuid and electrolyte management, but does not alter
the course of AKI and does not change the eventual need for
dialysis or overall mortality. Importantly, diuretics may delay
the start of RRT otherwise indicated. If medical therapies
are not successful, or if the patient is in extremis such that
diuretics seem unlikely to prove eﬀective, ﬂuid removal by
RRT is the deﬁnitive answer.
7.3. Medical Management of Metabolic Acidosis. Adverse ef-
fects of acute metabolic acidosis primarily include decreased
cardiac output, arterial dilatation with hypotension, altered
oxygen delivery, decreased ATP production, predisposition
to arrhythmias, and impairment of the immune response.
In patients with severe metabolic acidosis (pH < 7.1) and
evidence of cardiovascular compromise, administration of
NaHCO3 shouldbeconsideredtomaintainbloodpHat ∼7.2
[42]. If NaHCO3 is administered, it should be given as an
isotonic preparation (to prevent hyperosmolality) and as a
slow infusion rather than an intravenous bolus (to reduce
generation of CO2), in quantities designed to raise blood pH
to levels not greater than 7.2. Isotonic (1.26%) solutions may
also have a role in stable patients with a moderate to severe
acidosis and a requirement for ﬂuid replacement, in whom
RRT is not imminent.
7.4. Management of Uraemic Pericarditis. The prevalence of
uraemic pericarditis in patients with acute or chronic kidney
disease is 6–10%. Aﬀected patients are often asymptomatic
but may be complaining of chest pain. They often have a
small to moderate pericardial eﬀu s i o nw h i c hc a np r o g r e s st o
signiﬁcant haemodynamic compromise. The only therapy is
RRT and pericardiocentesis in case of signiﬁcant pericardial
eﬀusions. Therefore, the presence of a pericardial rub on
clinicalexaminationandclassicECGchangesconsistentwith
pericarditis are indications for urgent RRT and an urgent
echocardiogram.
8.FutureDevelopments
The characterisation of novel AKI biomarkers has improved
the understanding of the pathophysiology of AKI and pro-
vided tools to diagnose AKI earlier than serum creatinine.
Neutrophil gelatinase-associated lipocalin (NGAL) is one of
themostpromisingnewbiomarkersandhasbeenextensively
studied in diﬀerent patient populations [43, 44]. In a pro-
spective study of 635 adults presenting to the ED, a single
elevated urinary NGAL result was shown to predict the
development of AKI, need for RRT and/or need for ICU
admission [45]. More research is necessary to determine the
role of these new biomarkers in clinical practice.
9. Conclusions
ED physicians should consider the possibility of AKI or
incipient AKI in all of their critically ill patients and re-
member that even small rises in serum creatinine are asso-
ciated with detrimental short- and long-term eﬀects. At-risk
patientsneedtobeidentiﬁedearly.Fluidandhaemodynamic
resuscitation should be prompt, but patients need to be
regularly monitored and reviewed to prevent ﬂuid overload.
There is no curative therapy for AKI. Secondary prevention
with cessation of nephrotoxic medications is essential. More
research is necessary to explore whether any other strategies
in the ED could improve the prognosis of patients with AKI.
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